David B. Badesch
Department of Medicine
University of Colorado Denver
Denver
Colorado
USA
Name/email consistency: high
- Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. Badesch, D.B., McGoon, M.D., Barst, R.J., Tapson, V.F., Rubin, L.J., Wigley, F.M., Kral, K.M., Raphiou, I.H., Crater, G.D. J. Rheumatol. (2009)
- Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. Badesch, D.B., Hill, N.S., Burgess, G., Rubin, L.J., Barst, R.J., Galiè, N., Simonneau, G. J. Rheumatol. (2007)
- Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Badesch, D.B., Abman, S.H., Simonneau, G., Rubin, L.J., McLaughlin, V.V. Chest (2007)
- Prostanoid therapy for pulmonary arterial hypertension. Badesch, D.B., McLaughlin, V.V., Delcroix, M., Vizza, C.D., Olschewski, H., Sitbon, O., Barst, R.J. J. Am. Coll. Cardiol. (2004)
- Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Badesch, D.B., Abman, S.H., Ahearn, G.S., Barst, R.J., McCrory, D.C., Simonneau, G., McLaughlin, V.V. Chest (2004)
- Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., Rich, S., Barst, R.J., Barrett, P.S., Kral, K.M., Jöbsis, M.M., Loyd, J.E., Murali, S., Frost, A., Girgis, R., Bourge, R.C., Ralph, D.D., Elliott, C.G., Hill, N.S., Langleben, D., Schilz, R.J., McLaughlin, V.V., Robbins, I.M., Groves, B.M., Shapiro, S., Medsger, T.A. Ann. Intern. Med. (2000)
- Clinical trials in pulmonary hypertension. Badesch, D.B. Annu. Rev. Med. (1997)